NCT01604889 2026-04-21A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaIncyte CorporationPhase 1/2 Terminated50 enrolled